Why is Henry Schein stock sliding today?

Henry Schein shares fell nearly 5% after Q3 2026 revenue of $3.47B narrowly missed the $3.48B consensus, despite non-GAAP EPS of $1.56 beating the $1.36 estimate. Investors weighed 3.1% organic revenue growth and EPS benefits partly attributable to one-time tariff refunds, alongside planned Q4 growth investments that could pressure margins. The company raised full-year non-GAAP EPS guidance to $5.50–$5.56 from a prior consensus of $5.39 and lifted its adjusted EBITDA growth outlook to the high single digits; shares traded at $82.31 after an intraday low of $81.05.

Analysis

The key issue is conversion of reported EPS into repeatable earnings, not the tiny revenue shortfall. A tariff refund makes the beat a weaker read-through to the run rate, while planned Q4 customer-acquisition spending creates a near-term margin-versus-growth tradeoff. If that spending converts episodic buyers into recurring accounts, it could strengthen HSIC’s competitive position; if not, investors may mark down earnings quality without getting durable growth in return.

The 8.6% U.S. dental merchandise growth alongside 3.1% consolidated organic growth suggests demand is uneven across businesses or geographies. Verify segment-level growth and customer retention before extrapolating the U.S. result. Patterson Companies could face share pressure if HSIC’s volume gains persist; dental manufacturers such as Dentsply Sirona may benefit indirectly from stronger distributor sell-through, but the article gives no evidence of an industry-wide demand acceleration.

Near term, the company-specific selloff can persist as investors test whether higher spending dilutes margins. Over 1–3 months, the decisive evidence is organic growth, repeat purchasing and adjusted profitability excluding tariff-related benefits. Over 6–18 months, successful customer conversion would support share gains; weak conversion would leave HSIC with higher acquisition costs and less credible guidance. The contrarian case is that raised full-year EPS and EBITDA-growth outlook may limit downside if spending is temporary and organic demand holds. No valuation data are provided, so the size of any overreaction cannot be established.

Key Decisions for Investors

• Avoid buying solely on the raised guidance or the one-day decline. Treat HSIC as a watch rather than a high-conviction trade until the next update clarifies recurring earnings and Q4 spending.
• For an existing HSIC position, use the $81.05 intraday low as a near-term risk marker, not a fundamental value estimate. A sustained break below it would argue against a quick mean-reversion thesis; stabilization above it is not by itself confirmation.
• Watch the next reported organic growth, dental merchandise volume, customer retention/conversion indicators, and adjusted earnings excluding tariff-refund effects. Evidence of weak conversion or margin slippage would strengthen the downside case; sustained growth with stable underlying profitability would falsify it.
• Monitor Patterson Companies for signs that HSIC’s reported U.S. volume and share gains are taking business from competitors, and Dentsply Sirona for corroboration in manufacturer sell-through. Without that evidence, avoid extending HSIC-specific weakness into a broad dental-sector short.